Research projects conducted by the German Breast Group
The German Breast Group is researching breast cancer and implementing self-developed study concepts.
With the help of additional scientific research projects, we try to gain further insights into this disease.
Research News
10.04.2019 Results from E-VITA trial conducted with HER2-positive metastatic breast cancer patients
We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer has been published in the Anticancer Drugs.
01.03.2019 Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab
A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.
01.02.2019 Results of the GeparOcto trial
We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.
18.01.2019 Prof. Loibl unter den meist zitierten Wissenschaftlern in 2018
Prof. Dr. Sibylle Loibl gehört im Jahr 2018 mit Ihrer Arbeit im Bereich der Brustkrebsforschung zu den 1% der am meisten zitierten Wissenschaftlern.
17.12.2018 Results of an interim analysis from KATHERINE trial
We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.
Paper of the month
Every month, we present an interesting paper.
Read this month's paper now: "Palbociclib Combined with Fulvestrant in PremenopausalWomen with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results"
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440